Etiology and treatment of overactive bladder in women

Southern Medical Journal

Volumn 104, Issue 1, 2011, Pages 34-39

  Shaw, Howard A ^a   Burrows, Lara J ^a  

^a NONE

Author keywords

anticholinergics; antimuscarinics; neuromodulation; overactive bladder

Indexed keywords

ACETYLCHOLINE; ANTIDEPRESSANT AGENT; APREPITANT; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DULOXETINE; FESOTERODINE; IMIPRAMINE; MIRABEGRON; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ A; NEUROKININ B; NORADRENALIN; OXYBUTYNIN; PLACEBO; POTASSIUM ION; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SOLABEGRON; SOLIFENACIN; SUBSTANCE P; TOLTERODINE; TRAMADOL; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ARTICLE; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; BLADDER TRAINING; CAUCASIAN; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CYSTOMETRY; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; FEEDBACK SYSTEM; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MENTAL HEALTH; MICTURITION; MORBIDITY; NERVE STIMULATION; NEUROMODULATION; NOCTURIA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PELVIC FLOOR MUSCLE TRAINING; PHYSICAL EXAMINATION; POSTVOID RESIDUAL URINE VOLUME; POTASSIUM URINE LEVEL; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; TIBIAL NERVE; UNITED STATES; URGE INCONTINENCE; URINALYSIS; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; URINE PH; URINE VOLUME; URODYNAMICS; WOMEN'S HEALTH; XEROSTOMIA;

BEHAVIOR THERAPY; DEPRESSION; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; URINARY BLADDER, OVERACTIVE;

EID: 78650871486     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181faec80     Document Type: Article

References (49)

1. Abrams P, Cardozo L, Fall M, et al; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Uro-dyn. 2002; 21: 167-178 (Pubitemid 34195211)
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-766.
3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336.
4. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50:1306-1315.
5. McGrother CW, Donaldson MM, Hayward T, et al; Leicestershire MRC Incontinence Study Team. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006;35:16-24.
6. Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int 2007;99:502-509. (Pubitemid 46238818)
7. Mardon RE, Halim S, Pawlson LG, et al. Management of urinary incontinence in Medicare managed care beneficiaries: results from the 2004 Medicare Health Outcomes Survey. Arch Intern Med 2006;166: 1128-1133.
8. Griffiths AN, Makam A, Edwards GJ. Should we actively screen for urinary and anal incontinence in the general gynaecology outpatients setting a prospective observational study. J Obstet Gynaecol 2006; 26:442-444.
9. Harris SS, Link CL, Tennstedt SL, et al. Care seeking and treatment for urinary incontinence in a diverse population. J Urol 2007;177:680-684.
10. Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006;97:96-100.
11. De Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001;41:691-721.
12. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004;56:581-631.
13. Wein AJ. Pathophysiology and categorization of voiding dysfunction, in Walsh P, Retik A, Vaughan ED Jr, et al (eds): Campbell's Urology. Philadelphia, Saunders, 2002, ed 8, pp 887.
14. De Groat WC. The urothelium in overactive bladder: passive bystander or active participant? Urology 2004;64(6 suppl 1):7-11.
15. Basra R, Artibani W, Cardozo L, et al. Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). Eur Urol 2007;52:230-237.
16. Coyne KS, Zyczynski T, Margolis MK, et al. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005; 22:381-394.
17. Coyne KS, Matza LS, Thompson CL. The responsiveness of the over-active bladder questionnaire (OAB-Q). Qual Life Res 2005;14:849-855.
18. Blaivas JG, Panagopoulos G, Weiss JP, et al. Validation of the overac-tive bladder symptom score. J Urol 2007;178:543-547; discussion 547.
19. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;174:604-607.
20. Homma Y. The clinical significance of the urodynamic investigation in incontinence. BJU Int 2002;90:489-497.
21. Burgio KL. Influence of behavior modification on overactive bladder. Urology 2002;60(5 suppl 1):72-76; discussion 77.
22. Wilson PD, Berghmans B, Hagen S, et al. Adult conservative management, in Abrams P, Cardozo L, Khoury S, et al (eds): Incontinence Management. Paris, Health Publications, 2005, pp 855-894.
23. Wallace SA, Roe B, Williams K, et al. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 2004;1:CD001308.
24. Ouslander JG, Ai-Samarrai N, Schnelle JF. Prompted voiding for nighttime incontinence in nursing homes: is it effective? J Am Geriatr Soc 2001;49:706-709.
25. Burgio KL, Whitehead WE, Engel BT. Urinary incontinence in the elderly. Bladder-sphincter biofeedback and toileting skills training. Ann Intern Med 1985;103:507-515.
26. Brubaker L, Fanning K, Goldberg EL, et al. Predictors of discontinuing overactive bladder medications. BJU Int 2010;105:1283-1290.
27. Abrams P, Andersson KE. Muscarinic receptor antagonists for overac-tive bladder. BJU Int 2007; 100: 987-1006.
28. Chapple CR, Martinez-Garcia R, Selvaggi L, et al; for the STAR study group. A comparison of the efficacy and tolerability of solifenacin suc-cinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-470.
29. Chapple CR, Fianu-Jonsson A, Indig M, et al; STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 2007;52:1195-1203.
30. Hay-Smith J, Herbison P, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;3:CD005429.
31. Steers WD, Herschorn S, Kreder KJ, et al; Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007;100:337-345.
32. Duthie J, Wilson DI, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007;3:CD005493.
33. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007;52:850-858.
34. Reitz A, Denys P, Fermanian C, et al. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overac-tivity. Eur Urol 2007;52:1729-1735.
35. Mattiasson A, Blaakaer J, Høye K, et al. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int. 2003;91:54-60.
36. Chancellor MB, Kianifard F, Beamer E, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. Int J Clin Pract 2008;62:606-613.
37. Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol Res 2001;29:118-125.
38. Glazener CM, Evans JH, Peto RE. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev 2003;3: CD002117.
39. Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn 2007;26(6 suppl):934-947.
40. Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol 2001;39:101-106.
41. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178: 2029-2034.
42. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterod-ine: results from the overactive bladder innovative therapy trial. J Urol 2009;182:1055-1061.
43. Colli E, Digesu GA, Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 2007;16:999-1007.
44. Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel /33 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7:239.
45. Andersson KE, Pehrson R. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 2003;63:2595-2611.
46. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Phar-macokinet 2004;43:879-923.
47. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol 2006;61:456-463.
48. Ishizuka O, Igawa Y, Lecci A, et al. Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. Br J Pharmacol 1994;113:111-116.
49. Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:2535-2540.